Home
>
National Drug Code (NDC)
>
Didanosine
Didanosine - 0555-0589-01 - (Didanosine)
Drug Information of Didanosine
| Product NDC: | 0555-0589 |
| Proprietary Name: | Didanosine |
| Non Proprietary Name: | Didanosine |
| Active Ingredient(s): | 250 mg/1 & nbsp; Didanosine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE, DELAYED RELEASE PELLETS |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Didanosine
| Product NDC: | 0555-0589 |
| Labeler Name: | Barr Laboratories Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077167 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20041215 |
Package Information of Didanosine
| Package NDC: | 0555-0589-01 |
| Package Description: | 30 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0555-0589-01) |
NDC Information of Didanosine
| NDC Code | 0555-0589-01 |
| Proprietary Name | Didanosine |
| Package Description | 30 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0555-0589-01) |
| Product NDC | 0555-0589 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Didanosine |
| Dosage Form Name | CAPSULE, DELAYED RELEASE PELLETS |
| Route Name | ORAL |
| Start Marketing Date | 20041215 |
| Marketing Category Name | ANDA |
| Labeler Name | Barr Laboratories Inc. |
| Substance Name | DIDANOSINE |
| Strength Number | 250 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
